New drug avoids treatment problem for hepatitis C patients

10/31/2006 | HealthDay News

Researchers say hepatitis C patients with cirrhosis and low platelet levels can take standard antiviral medications if they also use the new drug eltrombopag. Two common drugs, ribavirin and pegylated interferon, further reduce platelet levels in patients, but eltrombopag counters that effect.

View Full Article in:

HealthDay News

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Chief Executive Officer
CarePoint Health Plan
Jersey City, NJ
Regional Director, Southeastern Region - State Affairs
America's Heatlh Insurance Plans (AHIP)
Washington, DC
Pharmacy Care Manager
National Association of Chain Drug Stores
Arlington, VA
Senior Director, Research
America's Health Insurance Plans (AHIP)
Washington, DC
Director, Compliance - Health Plan Privacy & Security
Kaiser Permanente
Oakland, CA